NUDHL1 and OCILY-19 DLBCL cells were also included as they express comparatively high levels of SLC16A3 (MCT4 gene) mRNA (Supplementary Fig. S1a), and were therefore considered likely to demonstrate resistance to MCT1 inhibition. This evidence concerns the gene SLC16A1 and diffuse large B-cell lymphoma.